Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there’s been only one gene-editing drug approved. It’s been used commercially on only about 40 patients, all with sickle-cell disease. It’s becoming clear that the impact of CRISPR…
Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest biotech breakthrough of the century. Yet so far, there’s been only one gene-editing drug approved. It’s been used commerciall… [4426 chars]
Source: MIT Technology Review | Published: 2026-01-09T11:00:00Z
Credit: MIT Technology Review
